-
1
-
-
67449124637
-
The development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal
-
Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68 (6): 770-6
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.6
, pp. 770-776
-
-
Rudwaleit, M.1
Landewé, R.2
Van Der Heijde, D.3
-
2
-
-
67449128733
-
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection
-
Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68 (6): 777-83
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.6
, pp. 777-783
-
-
Rudwaleit, M.1
Van Der Heijde, D.2
Landewe, R.3
-
3
-
-
0021272107
-
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria
-
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27 (4): 361-8
-
(1984)
Arthritis Rheum
, vol.27
, Issue.4
, pp. 361-368
-
-
Van Der Linden, S.1
Valkenburg, H.A.2
Cats, A.3
-
4
-
-
78650679234
-
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
-
RudwaleitM, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70 (1): 25-31
-
(2011)
Ann Rheum Dis
, vol.70
, Issue.1
, pp. 25-31
-
-
Rudwaleit, M.1
Van Der Heijde, D.2
Landewé, R.3
-
5
-
-
33746951437
-
Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
-
Taylor W, Gladman D, Helliwell P, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54 (8): 2665-73
-
(2006)
Arthritis Rheum
, vol.54
, Issue.8
, pp. 2665-2673
-
-
Taylor, W.1
Gladman, D.2
Helliwell, P.3
-
6
-
-
79955826864
-
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
-
Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70 (6): 896-904
-
(2011)
Ann Rheum Dis
, vol.70
, Issue.6
, pp. 896-904
-
-
Braun, J.1
Van Den Berg, R.2
Baraliakos, X.3
-
7
-
-
79955844276
-
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
-
van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70 (6): 905-8
-
(2011)
Ann Rheum Dis
, vol.70
, Issue.6
, pp. 905-908
-
-
Van Der Heijde, D.1
Sieper, J.2
Maksymowych, W.P.3
-
8
-
-
82955236087
-
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
-
European League Against Rheumatism
-
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71 (1): 4-12
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.1
, pp. 4-12
-
-
Gossec, L.1
Smolen, J.S.2
Gaujoux-Viala, C.3
-
9
-
-
84889634412
-
Treating spondyloarthritis including ankylosing spondylitis and psoriatic arthritis to target: Recommendations of an international task force
-
Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73 (1): 6-16
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.1
, pp. 6-16
-
-
Smolen, J.S.1
Braun, J.2
Dougados, M.3
-
10
-
-
0037029430
-
Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial
-
Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313): 1187-93
-
(2002)
Lancet
, vol.359
, Issue.9313
, pp. 1187-1193
-
-
Braun, J.1
Brandt, J.2
Listing, J.3
-
11
-
-
79958051264
-
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized double-blind trial
-
Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63 (6): 1543-51
-
(2011)
Arthritis Rheum
, vol.63
, Issue.6
, pp. 1543-1551
-
-
Braun, J.1
Van Der Horst-Bruinsma, I.E.2
Huang, F.3
-
12
-
-
84859509505
-
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
-
Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012; 71 (5): 661-7
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.5
, pp. 661-667
-
-
Braun, J.1
Deodhar, A.2
Inman, R.D.3
-
13
-
-
84877606429
-
Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: Results of a randomised placebocontrolled trial (ABILITY-1)
-
Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebocontrolled trial (ABILITY-1). Ann Rheum Dis 2013; 72 (6): 815-22
-
(2013)
Ann Rheum Dis
, vol.72
, Issue.6
, pp. 815-822
-
-
Sieper, J.1
Van Der Heijde, D.2
Dougados, M.3
-
14
-
-
84889654076
-
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
-
Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73 (1): 39-47
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.1
, pp. 39-47
-
-
Landewe, R.1
Braun, J.2
Deodhar, A.3
-
15
-
-
84904957534
-
The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis
-
Dougados M, van der Heijde D, Sieper J, et al. The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2014; 66 (8): 2091-102
-
(2014)
Arthritis Rheumatol
, vol.66
, Issue.8
, pp. 2091-2102
-
-
Dougados, M.1
Van Der Heijde, D.2
Sieper, J.3
-
16
-
-
84860896324
-
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised placebocontrolled GO-RAISE study
-
Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebocontrolled GO-RAISE study. Ann Rheum Dis 2012; 71 (6): 878-84
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.6
, pp. 878-884
-
-
Braun, J.1
Baraliakos, X.2
Hermann, K.G.3
-
17
-
-
84859466376
-
Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement
-
Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012; 39 (4): 836-40
-
(2012)
J Rheumatol
, vol.39
, Issue.4
, pp. 836-840
-
-
Braun, J.1
Pavelka, K.2
Ramos-Remus, C.3
-
18
-
-
84898441760
-
Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis
-
Braun J, Baraliakos X, Heldmann F, Kiltz U. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Investig Drugs 2014; 23 (5): 647-59
-
(2014)
Expert Opin Investig Drugs
, vol.23
, Issue.5
, pp. 647-659
-
-
Braun, J.1
Baraliakos, X.2
Heldmann, F.3
Kiltz, U.4
-
19
-
-
84883746909
-
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study
-
Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 10): 1605-12
-
(2013)
Ann Rheum Dis
, vol.10
, pp. 1605-1612
-
-
Park, W.1
Hrycaj, P.2
Jeka, S.3
-
20
-
-
65249142737
-
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis
-
Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis. Arthritis Rheum 2009; 60 (4): 946-54
-
(2009)
Arthritis Rheum
, vol.60
, Issue.4
, pp. 946-954
-
-
Barkham, N.1
Keen, H.I.2
Coates, L.C.3
-
21
-
-
65249142737
-
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis
-
Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis. Arthritis Rheum 2009; 60 (4): 946-54
-
(2009)
Arthritis Rheum
, vol.60
, Issue.4
, pp. 946-954
-
-
Barkham, N.1
Keen, H.I.2
Coates, L.C.3
-
22
-
-
84885797466
-
Remission and possible discontinuation of biological therapy in axial spondyloarthritis
-
Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S33-6
-
(2013)
Clin Exp Rheumatol
, vol.31
, Issue.4
, pp. S33-S36
-
-
Braun, J.1
Sieper, J.2
-
23
-
-
80051920383
-
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome
-
Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011; 50 (9): 1690-9
-
(2011)
Rheumatology (Oxford)
, vol.50
, Issue.9
, pp. 1690-1699
-
-
Baraliakos, X.1
Listing, J.2
Fritz, C.3
-
24
-
-
84879071427
-
Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
-
Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013; 15 (3): R67
-
(2013)
Arthritis Res Ther
, vol.15
, Issue.3
, pp. R67
-
-
Baraliakos, X.1
Haibel, H.2
Fritz, C.3
-
25
-
-
84899971267
-
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: Results through 4 years of the GO-RAISE trial
-
Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014; 73 (6): 1107-13
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.6
, pp. 1107-1113
-
-
Braun, J.1
Baraliakos, X.2
Hermann, K.G.3
-
26
-
-
84895490291
-
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis
-
Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2013; 73 (4): 710-15
-
(2013)
Ann Rheum Dis
, vol.73
, Issue.4
, pp. 710-715
-
-
Baraliakos, X.1
Haibel, H.2
Listing, J.3
-
27
-
-
85027908446
-
Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis
-
[Epub ahead of print]
-
Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2014. [Epub ahead of print]
-
(2014)
Ann Rheum Dis
-
-
Haroon, M.1
Gallagher, P.2
Fitzgerald, O.3
-
28
-
-
0034729950
-
Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
-
Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356 (9227): 385-90
-
(2000)
Lancet
, vol.356
, Issue.9227
, pp. 385-390
-
-
Mease, P.J.1
Goffe, B.S.2
Metz, J.3
-
29
-
-
19044382942
-
IMPACT 2 Trial Investigators Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial
-
Antoni C, Krueger GG, de Vlam K, et al. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64 (8): 1150-7
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.8
, pp. 1150-1157
-
-
Antoni, C.1
Krueger, G.G.2
De Vlam, K.3
-
30
-
-
26844432745
-
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebocontrolled trial
-
Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum 2005; 52 (10): 3279-89
-
(2005)
Arthritis Rheum
, vol.52
, Issue.10
, pp. 3279-3289
-
-
Mease, P.J.1
Gladman, D.D.2
Ritchlin, C.T.3
-
31
-
-
84889668023
-
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
-
Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73 (1): 48-55
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.1
, pp. 48-55
-
-
Mease, P.J.1
Fleischmann, R.2
Deodhar, A.A.3
-
32
-
-
84905083653
-
Clinical efficacy radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a longterm extension of a randomised placebocontrolled trial the GO-REVEAL study
-
Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a longterm extension of a randomised, placebocontrolled trial, the GO-REVEAL study. Ann Rheum Dis 2014; 73 (9): 1689-94
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.9
, pp. 1689-1694
-
-
Kavanaugh, A.1
McInnes, I.B.2
Mease, P.3
-
33
-
-
84885181527
-
Clinical efficacy radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised placebo-controlled GO-REVEAL study
-
Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013; 72 (11): 1777-85
-
(2013)
Ann Rheum Dis
, vol.72
, Issue.11
, pp. 1777-1785
-
-
Kavanaugh, A.1
McInnes, I.B.2
Mease, P.J.3
-
34
-
-
84889657887
-
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: Results of the RAPID-PsA 24-week phase III doubleblind randomised placebo-controlled study of certolizumab pegol
-
van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III doubleblind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014; 73 (1): 233-7
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.1
, pp. 233-237
-
-
Van Der Heijde, D.1
Fleischmann, R.2
Wollenhaupt, J.3
-
35
-
-
84859495141
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
-
Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 (Suppl 2): i2-i45
-
(2012)
Ann Rheum Dis
, vol.71
, pp. i2-i45
-
-
Furst, D.E.1
Keystone, E.C.2
Braun, J.3
-
36
-
-
85027914552
-
Golimumab 3-year safety update: An analysis of pooled data from the longterm extensions of randomised, doubleblind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
-
[Epub ahead of print]
-
Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the longterm extensions of randomised, doubleblind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2013. [Epub ahead of print]
-
(2013)
Ann Rheum Dis
-
-
Kay, J.1
Fleischmann, R.2
Keystone, E.3
-
37
-
-
84920867646
-
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A multicentre, open-label, randomised controlled trial
-
Coates L, Moverley A, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. Lancet 2014; 383: S36
-
(2014)
Lancet
, vol.383
, pp. S36
-
-
Coates, L.1
Moverley, A.2
McParland, L.3
-
38
-
-
84903848853
-
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort
-
Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014; 73 (8): 1455-61
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.8
, pp. 1455-1461
-
-
Ramiro, S.1
Van Der Heijde, D.2
Van Tubergen, A.3
-
39
-
-
84859255344
-
Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: Are there alternatives?
-
Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol 2012; 24 (3): 252-60
-
(2012)
Curr Opin Rheumatol
, vol.24
, Issue.3
, pp. 252-260
-
-
Kiltz, U.1
Heldmann, F.2
Baraliakos, X.3
Braun, J.4
-
40
-
-
84923280531
-
Stellungnahme der Deutschen Gesellschaft für Rheumatologie zur Einführung und Gebrauch von Biosimilars in der Therapie entzündlich-rheumatischer Erkrankungen
-
Lorenz HM, Braun J, Krüger K, Schneider M. Stellungnahme der Deutschen Gesellschaft für Rheumatologie zur Einführung und Gebrauch von Biosimilars in der Therapie entzündlich-rheumatischer Erkrankungen. Z Rheumatol 2014; 73 (9): 784-6
-
(2014)
Z Rheumatol
, vol.73
, Issue.9
, pp. 784-786
-
-
Lorenz, H.M.1
Braun, J.2
Krüger, K.3
Schneider, M.4
-
42
-
-
84923304115
-
Progress in biosimilar monoclonal antibody development: The infliximab biosimilar CT-P13 in the treatment of rheumatic diseases
-
In press
-
Braun J. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy 2014; In press
-
(2014)
Immunotherapy
-
-
Braun, J.1
-
43
-
-
84923302900
-
New targets in psoriatic arthritis
-
In press
-
Braun J. New targets in psoriatic arthritis. Rheumatology 2014; In press
-
(2014)
Rheumatology
-
-
Braun, J.1
-
44
-
-
85027912491
-
Development of a health index in patients with ankylosing spondylitis (ASAS HI): Final result of a global initiative based on the ICF guided by ASAS
-
[Epub ahead of print]
-
Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2014. [Epub ahead of print]
-
(2014)
Ann Rheum Dis
-
-
Kiltz, U.1
Van Der Heijde, D.2
Boonen, A.3
-
45
-
-
84899825889
-
A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) question-naire, a 13-country EULAR initiative
-
EULAR PsAID Taskforce
-
Gossec L, de Wit M, Kiltz U, et al. EULAR PsAID Taskforce. A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) question-naire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73 (6): 1012-19
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.6
, pp. 1012-1019
-
-
Gossec, L.1
De Wit, M.2
Kiltz, U.3
-
46
-
-
84887432536
-
Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: Changes after 2 years of tumor necrosis factor inhibitor therapy
-
Baraliakos X, Listing J, Haibel H, et al. Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol 2013; 40 (11): 1891-6
-
(2013)
J Rheumatol
, vol.40
, Issue.11
, pp. 1891-1896
-
-
Baraliakos, X.1
Listing, J.2
Haibel, H.3
-
47
-
-
84881071746
-
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography
-
Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 2013; 73 (10): 1819-25
-
(2013)
Ann Rheum Dis
, vol.73
, Issue.10
, pp. 1819-1825
-
-
Baraliakos, X.1
Heldmann, F.2
Callhoff, J.3
-
48
-
-
84923300192
-
Randomized controlled trial of adalimumab in patients with peripheral spondyloarthritis
-
Mease P, Sieper J, van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with peripheral spondyloarthritis. Arthritis Rheum 2012; 64 (suppl10): 570 doi: 10.1002/art.38305
-
(2012)
Arthritis Rheum
, vol.64
, pp. 570
-
-
Mease, P.1
Sieper, J.2
Van Den Bosch, F.3
-
49
-
-
84884411389
-
Genetics of ankylosing spondylitis
-
Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Mol Immunol 2014; 57 (1): 2-11
-
(2014)
Mol Immunol
, vol.57
, Issue.1
, pp. 2-11
-
-
Robinson, P.C.1
Brown, M.A.2
-
50
-
-
84882449068
-
Genetic insights into common pathways and complex relationships among immune-mediated diseases
-
Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14 (9): 661-73
-
(2013)
Nat Rev Genet
, vol.14
, Issue.9
, pp. 661-673
-
-
Parkes, M.1
Cortes, A.2
Van Heel, D.A.3
Brown, M.A.4
-
51
-
-
84896313565
-
The IL-23/IL-17 axis in psoriatic arthritis
-
Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014; 13 (4-5): 496-502
-
(2014)
Autoimmun Rev
, vol.13
, Issue.4-5
, pp. 496-502
-
-
Suzuki, E.1
Mellins, E.D.2
Gershwin, M.E.3
-
52
-
-
69349093225
-
Interleukin-17 and type 17 helper T cells
-
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98
-
(2009)
N Engl J Med
, vol.361
, pp. 888-898
-
-
Miossec, P.1
Korn, T.2
Kuchroo, V.K.3
-
53
-
-
84863697312
-
IL-23 induces spondyloarthropathy by acting on ROR-gt+ CD3+CD4-CD8-entheseal resident T cells
-
Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012; 18: 1069-76
-
(2012)
Nat Med
, vol.18
, pp. 1069-1076
-
-
Sherlock, J.P.1
Joyce-Shaikh, B.2
Turner, S.P.3
-
55
-
-
66449133523
-
Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis
-
Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 1647-56
-
(2009)
Arthritis Rheum
, vol.60
, pp. 1647-1656
-
-
Shen, H.1
Goodall, J.C.2
Hill Gaston, J.S.3
-
56
-
-
79951835541
-
Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis
-
Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011; 186: 2672-80
-
(2011)
J Immunol
, vol.186
, pp. 2672-2680
-
-
Bowness, P.1
Ridley, A.2
Shaw, J.3
-
57
-
-
82455210509
-
Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response
-
Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum 2011; 63: 3807-17
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3807-3817
-
-
Zeng, L.1
Lindstrom, M.J.2
Smith, J.A.3
-
58
-
-
84858644639
-
Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive g/d T cells in patients with active ankylosing spondylitis
-
Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive g/d T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012; 64: 1420-9
-
(2012)
Arthritis Rheum
, vol.64
, pp. 1420-1429
-
-
Kenna, T.J.1
Davidson, S.I.2
Duan, R.3
-
59
-
-
79959207913
-
Analysis of IL-17 (+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
-
Appel H, Maier R, Wu P, et al. Analysis of IL-17 (+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13: R95
-
(2011)
Arthritis Res Ther
, vol.13
, pp. R95
-
-
Appel, H.1
Maier, R.2
Wu, P.3
-
60
-
-
84878527072
-
In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis
-
Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013; 65 (6): 1522-9
-
(2013)
Arthritis Rheum
, vol.65
, Issue.6
, pp. 1522-1529
-
-
Appel, H.1
Maier, R.2
Bleil, J.3
-
61
-
-
84855291352
-
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
-
Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64: 99-109
-
(2012)
Arthritis Rheum
, vol.64
, pp. 99-109
-
-
Noordenbos, T.1
Yeremenko, N.2
Gofita, I.3
-
62
-
-
33846889522
-
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
-
Krueger GG, Langley RG, Leonardi C, et al. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (6): 580-92
-
(2007)
N Engl J Med
, vol.356
, Issue.6
, pp. 580-592
-
-
Krueger, G.G.1
Langley, R.G.2
Leonardi, C.3
-
63
-
-
43449111187
-
PHOENIX 1 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
Leonardi CL, Kimball AB, Papp KA, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1665-74
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
-
64
-
-
43449139402
-
PHOENIX 2 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2)
-
Papp KA, Langley RG, Lebwohl M, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625): 1675-84
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
-
65
-
-
74249094930
-
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
-
Griffiths CE, Strober BE, van de Kerkhof P, et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362 (2): 118-28
-
(2010)
N Engl J Med
, vol.362
, Issue.2
, pp. 118-128
-
-
Griffiths, C.E.1
Strober, B.E.2
Van De Kerkhof, P.3
-
66
-
-
60249084148
-
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial
-
Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373 (9664): 633-40
-
(2009)
Lancet
, vol.373
, Issue.9664
, pp. 633-640
-
-
Gottlieb, A.1
Menter, A.2
Mendelsohn, A.3
-
67
-
-
84883134297
-
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
-
McInnes IB, Kavanaugh A, Gottlieb AB, et al. PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382 (9894): 780-9
-
(2013)
Lancet
, vol.382
, Issue.9894
, pp. 780-789
-
-
McInnes, I.B.1
Kavanaugh, A.2
Gottlieb, A.B.3
-
68
-
-
84899991797
-
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
-
Ritchlin C, Rahman P, Kavanaugh A, et al. on behalf of the PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73 (6): 990-9
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.6
, pp. 990-999
-
-
Ritchlin, C.1
Rahman, P.2
Kavanaugh, A.3
-
69
-
-
84899922972
-
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
-
Kavanaugh A, Ritchlin C, Rahman P, et al. on behalf of the PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73 (6): 1000-6
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.6
, pp. 1000-1006
-
-
Kavanaugh, A.1
Ritchlin, C.2
Rahman, P.3
-
70
-
-
84897980960
-
Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
-
Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014; 73 (5): 817-23
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.5
, pp. 817-823
-
-
Poddubnyy, D.1
Hermann, K.G.2
Callhoff, J.3
-
71
-
-
84871701834
-
Ustekinumab induction and maintenance therapy in refractory Crohn's disease
-
Sandborn WJ, Gasink C, Gao LL, et al. CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367 (16): 1519-28
-
(2012)
N Engl J Med
, vol.367
, Issue.16
, pp. 1519-1528
-
-
Sandborn, W.J.1
Gasink, C.2
Gao, L.L.3
-
72
-
-
53049091561
-
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
-
Sandborn WJ, Feagan BG, Fedorak RN, et al. Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135 (4): 1130-41
-
(2008)
Gastroenterology
, vol.135
, Issue.4
, pp. 1130-1141
-
-
Sandborn, W.J.1
Feagan, B.G.2
Fedorak, R.N.3
-
73
-
-
84897146802
-
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
-
Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133 (4): 1032-40
-
(2014)
J Allergy Clin Immunol
, vol.133
, Issue.4
, pp. 1032-1040
-
-
Sofen, H.1
Smith, S.2
Matheson, R.T.3
-
74
-
-
84899748064
-
Emerging evidence for critical involvement of the IL17 pathway in both psoriasis and psoriatic arthritis
-
Fitzgerald O, Winchester R. Emerging evidence for critical involvement of the IL17 pathway in both psoriasis and psoriatic arthritis. Arthritis Rheumatol 2014; 66 (5): 1077-80
-
(2014)
Arthritis Rheumatol
, vol.66
, Issue.5
, pp. 1077-1080
-
-
Fitzgerald, O.1
Winchester, R.2
-
75
-
-
84876292569
-
Effect of IL-17A blockade with secukinumab in autoimmune diseases
-
Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72: Suppl 2 ii116-23
-
(2013)
Ann Rheum Dis
, vol.72
, pp. ii116-ii123
-
-
Patel, D.D.1
Lee, D.M.2
Kolbinger, F.3
Antoni, C.4
-
76
-
-
84868680312
-
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial
-
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61 (12): 1693-700
-
(2012)
Gut
, vol.61
, Issue.12
, pp. 1693-1700
-
-
Hueber, W.1
Sands, B.E.2
Lewitzky, S.3
-
77
-
-
84875697084
-
Secukinumab in the treatment of noninfectious uveitis: Results of three randomized controlled clinical trials
-
Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120 (4): 777-87
-
(2013)
Ophthalmology
, vol.120
, Issue.4
, pp. 777-787
-
-
Dick, A.D.1
Tugal-Tutkun, I.2
Foster, S.3
-
78
-
-
84873168729
-
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimenfinding study
-
Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimenfinding study. Br J Dermatol 2013; 168: 402-11
-
(2013)
Br J Dermatol
, vol.168
, pp. 402-411
-
-
Rich, P.1
Sigurgeirsson, B.2
Thaci, D.3
-
79
-
-
84873124241
-
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, doubleblind, placebo-controlled phase II doseranging study
-
Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, doubleblind, placebo-controlled phase II doseranging study. Br J Dermatol 2013; 168 (2): 412-21
-
(2013)
Br J Dermatol
, vol.168
, Issue.2
, pp. 412-421
-
-
Papp, K.A.1
Langley, R.G.2
Sigurgeirsson, B.3
-
80
-
-
84904545875
-
Secukinumab in plaque psoriasis-results of two phase 3 trials
-
Langley RG, Elewski BE, Lebwohl M, et al. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371 (4): 326-38
-
(2014)
N Engl J Med
, vol.371
, Issue.4
, pp. 326-338
-
-
Langley, R.G.1
Elewski, B.E.2
Lebwohl, M.3
-
81
-
-
84891740105
-
Efficacy and safety of secukinumab a fully human anti-inter-leukin-17A monoclonal antibody in patients with moderate-to-severe psoriatic arthritis: A 24-week randomised doubleblind placebo-controlled phase II proof-of-concept trial
-
McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-inter-leukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, doubleblind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73 (2): 349-56
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.2
, pp. 349-356
-
-
McInnes, I.B.1
Sieper, J.2
Braun, J.3
-
82
-
-
84887992906
-
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised double-blind placebo-controlled trial
-
Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382 (9906): 1705-13
-
(2013)
Lancet
, vol.382
, Issue.9906
, pp. 1705-1713
-
-
Baeten, D.1
Baraliakos, X.2
Braun, J.3
-
83
-
-
84859017988
-
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
-
Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366 (13): 1181-9
-
(2012)
N Engl J Med
, vol.366
, Issue.13
, pp. 1181-1189
-
-
Papp, K.A.1
Leonardi, C.2
Menter, A.3
-
84
-
-
84902209516
-
Brodalumab, an anti-IL17RA mono-clonal antibody, in psoriatic arthritis
-
Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA mono-clonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370 (24): 2295-306
-
(2014)
N Engl J Med
, vol.370
, Issue.24
, pp. 2295-2306
-
-
Mease, P.J.1
Genovese, M.C.2
Greenwald, M.W.3
-
85
-
-
84859073115
-
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
-
Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366 (13): 1190-9
-
(2012)
N Engl J Med
, vol.366
, Issue.13
, pp. 1190-1199
-
-
Leonardi, C.1
Matheson, R.2
Zachariae, C.3
-
86
-
-
84901029678
-
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: Ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab
-
Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 2014; 18: 1-14
-
(2014)
J Cutan Med Surg
, vol.18
, pp. 1-14
-
-
Tausend, W.1
Downing, C.2
Tyring, S.3
-
87
-
-
84860920161
-
Association between the IL-1 family gene cluster and spondyloarthritis
-
Monnet D, Kadi A, Izac B, et al. Association between the IL-1 family gene cluster and spondyloarthritis. Ann Rheum Dis 2012; 71 (6): 885-90
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.6
, pp. 885-890
-
-
Monnet, D.1
Kadi, A.2
Izac, B.3
-
88
-
-
4344699365
-
Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study
-
Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63 (9): 1041-5
-
(2004)
Ann Rheum Dis
, vol.63
, Issue.9
, pp. 1041-1045
-
-
Tan, A.L.1
Marzo-Ortega, H.2
O'Connor, P.3
-
89
-
-
38649126902
-
Sustained response to anakinra in ankylosing spondylitis
-
Bennett AN, Tan AL, Coates LC, et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47 (2): 223-4
-
(2008)
Rheumatology (Oxford)
, vol.47
, Issue.2
, pp. 223-224
-
-
Bennett, A.N.1
Tan, A.L.2
Coates, L.C.3
-
90
-
-
13244279795
-
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
-
Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64 (2): 296-8
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.2
, pp. 296-298
-
-
Haibel, H.1
Rudwaleit, M.2
Listing, J.3
Sieper, J.4
-
91
-
-
79952113703
-
An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)
-
Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010; 29 (10): 1169-73
-
(2010)
Clin Rheumatol
, vol.29
, Issue.10
, pp. 1169-1173
-
-
Jung, N.1
Hellmann, M.2
Hoheisel, R.3
-
92
-
-
77951757221
-
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial
-
Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62 (5): 1290-7
-
(2010)
Arthritis Rheum
, vol.62
, Issue.5
, pp. 1290-1297
-
-
Song, I.H.1
Heldmann, F.2
Rudwaleit, M.3
-
93
-
-
84872086509
-
One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare
-
Song IH, Heldmann F, Rudwaleit M, et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 2013; 72 (2): 305-6
-
(2013)
Ann Rheum Dis
, vol.72
, Issue.2
, pp. 305-306
-
-
Song, I.H.1
Heldmann, F.2
Rudwaleit, M.3
-
94
-
-
84870318190
-
French Society of Rheumatology and the Club Rhumatismes et Inflammation. Rituximab treatment for spondyloarthritis. A nationwide series: Data from the AIR registry of the French Society of Rheumatology
-
Wendling D, Dougados M, Berenbaum F, et al. French Society of Rheumatology and the Club Rhumatismes et Inflammation. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012; 39 (12): 2327-31
-
(2012)
J Rheumatol
, vol.39
, Issue.12
, pp. 2327-2331
-
-
Wendling, D.1
Dougados, M.2
Berenbaum, F.3
-
95
-
-
84867401161
-
Rituximab in psoriatic arthritis: An exploratory evaluation
-
Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012; 71 (11): 1868-71
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.11
, pp. 1868-1871
-
-
Jimenez-Boj, E.1
Stamm, T.A.2
Sadlonova, M.3
-
96
-
-
79955868460
-
Treatment of active ankylosing spondylitis with abatacept: An open-label, 24-week pilot study
-
Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108-10
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1108-1110
-
-
Song, I.H.1
Heldmann, F.2
Rudwaleit, M.3
-
97
-
-
79953701653
-
Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month multicenter randomized double-blind placebo-controlled phase II trial
-
Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63 (4): 939-48
-
(2011)
Arthritis Rheum
, vol.63
, Issue.4
, pp. 939-948
-
-
Mease, P.1
Genovese, M.C.2
Gladstein, G.3
-
98
-
-
0028903218
-
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
-
Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38 (4): 499-505
-
(1995)
Arthritis Rheum
, vol.38
, Issue.4
, pp. 499-505
-
-
Braun, J.1
Bollow, M.2
Neure, L.3
-
99
-
-
78049418460
-
Mixed response to tocilizumab for ankylosing spondylitis
-
Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010; 69 (12): 2217-18
-
(2010)
Ann Rheum Dis
, vol.69
, Issue.12
, pp. 2217-2218
-
-
Henes, J.C.1
Horger, M.2
Guenaydin, I.3
-
100
-
-
84889684742
-
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomised, placebo-controlled trials
-
Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014; 73: 95-100
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 95-100
-
-
Sieper, J.1
Porter-Brown, B.2
Thompson, L.3
-
101
-
-
85027912860
-
Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebocontrolled study (ALIGN)
-
[Epub ahead of print]
-
Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebocontrolled study (ALIGN). Ann Rheum Dis 2014. [Epub ahead of print]
-
(2014)
Ann Rheum Dis
-
-
Sieper, J.1
Braun, J.2
Kay, J.3
-
102
-
-
84882992107
-
Successful use of tocilizumab in a patient with psoriatic arthritis
-
Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford) 2013; 52 (9): 1728-9
-
(2013)
Rheumatology (Oxford)
, vol.52
, Issue.9
, pp. 1728-1729
-
-
Hughes, M.1
Chinoy, H.2
-
103
-
-
84882372494
-
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: A phase II open-label study
-
Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013; 12 (8): 888-97
-
(2013)
J Drugs Dermatol
, vol.12
, Issue.8
, pp. 888-897
-
-
Gottlieb, A.B.1
Matheson, R.T.2
Menter, A.3
-
104
-
-
84865373941
-
Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial
-
Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380 (9843): 738-46
-
(2012)
Lancet
, vol.380
, Issue.9843
, pp. 738-746
-
-
Papp, K.1
Cather, J.C.2
Rosoph, L.3
-
105
-
-
84869014252
-
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter randomized double-blind placebo-controlled study
-
Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64 (10): 3156-67
-
(2012)
Arthritis Rheum
, vol.64
, Issue.10
, pp. 3156-3167
-
-
Schett, G.1
Wollenhaupt, J.2
Papp, K.3
-
106
-
-
84899981396
-
Treatment of psoriatic arthritis in a phase 3 randomised placebo-controlled trial with apremilast an oral phosphodiesterase 4 inhibitor
-
Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73 (6): 1020-6
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.6
, pp. 1020-1026
-
-
Kavanaugh, A.1
Mease, P.J.2
Gomez-Reino, J.J.3
-
107
-
-
84881475901
-
Efficacy and safety of apremilast an oral phosphodiesterase 4 inhibitor in ankylosing spondylitis
-
Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2013; 72 (9): 1475-80
-
(2013)
Ann Rheum Dis
, vol.72
, Issue.9
, pp. 1475-1480
-
-
Pathan, E.1
Abraham, S.2
Van Rossen, E.3
-
108
-
-
84865592373
-
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study
-
Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167 (3): 668-77
-
(2012)
Br J Dermatol
, vol.167
, Issue.3
, pp. 668-677
-
-
Papp, K.A.1
Menter, A.2
Strober, B.3
-
109
-
-
84879988459
-
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
-
Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169 (1): 137-45
-
(2013)
Br J Dermatol
, vol.169
, Issue.1
, pp. 137-145
-
-
Ports, W.C.1
Khan, S.2
Lan, S.3
-
110
-
-
84896372778
-
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions
-
Menter A, Papp KA, Tan H, et al. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014; 13 (3): 252-6
-
(2014)
J Drugs Dermatol
, vol.13
, Issue.3
, pp. 252-256
-
-
Menter, A.1
Papp, K.A.2
Tan, H.3
-
111
-
-
84885798581
-
Withdrawal of biologic therapy in axial spondyloarthritis: The experience in established disease
-
Baraliakos X, Kiltz U, Heldmann F, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S43-6
-
(2013)
Clin Exp Rheumatol
, vol.31
, Issue.4
, pp. S43-S46
-
-
Baraliakos, X.1
Kiltz, U.2
Heldmann, F.3
-
112
-
-
84885821934
-
Withdrawal of biologic therapy in axial spondyloarthritis: The experience in early disease
-
Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S37-42
-
(2013)
Clin Exp Rheumatol
, vol.31
, Issue.4
, pp. S37-42
-
-
Song, I.H.1
Haibel, H.2
Poddubnyy, D.3
-
113
-
-
84877809247
-
Immunogenicity and autoimmunity during anti-TNF therapy
-
Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013; 12 (7): 703-8
-
(2013)
Autoimmun Rev
, vol.12
, Issue.7
, pp. 703-708
-
-
Atzeni, F.1
Talotta, R.2
Salaffi, F.3
|